Skip to content
Loading...
All Sources
All Years

DECISION highlights at EASL Congress 2023

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts.…

Meet our EASL Emerging Leader Awardees 2023!

David Pinato and Lung Yi Mak have been awarded the prestigious EASL Emerging Leader Award, recognizing their outstanding contributions to liver research. The award, presented annually at the EASL Congress, is dedicated…

A-TANGO highlights at EASL Congress 2023

The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to…

MICROB-PREDICT highlights at EASL Congress 2023

MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to…

LITMUS highlights at EASL Congress 2023

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from…

Back To Top